GBT Global Blood Therapeutics Inc.

-0.86  -1%
Previous Close 63.29
Open 63.56
Price To Book 6.33
Market Cap 3,521,460,355
Shares 56,406,541
Volume 920,995
Short Ratio
Av. Daily Volume 826,075

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy.
Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest
NDA to be filed under accelerated approval 2H 2019. Data presented at EHA June 14, 2019 noted 51% patients showed a hemoglobin response.
Sickle cell disease
Phase 2 data to be presented at ASH December 3, 2018 noted 55% (6 of 11) achieved a hemoglobin response >1 g/dL .
Sickle cell disease - children age 6-17.

Latest News

  1. Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
  2. Should You Be Concerned About Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) Historical Volatility?
  3. Is Global Blood Therapeutics Inc (GBT) A Good Stock To Buy?
  4. Global Blood Therapeutics Stock Options Hot During Sell-Off
  5. GBT Announces Updated 24-Week Efficacy Data from All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor
  6. Options Traders Expect Huge Moves in Global Blood Therapeutics (GBT) Stock
  7. A Biotech Stock to Watch Now
  8. GBT Awards More than $200,000 in Grants to Five Nonprofit Organizations through New ACCEL Program Aimed at Improving Access to Healthcare for People Living with Sickle Cell Disease
  9. Why Is Global Blood (GBT) Up 2% Since Last Earnings Report?
  10. GBT Announces New Employment Inducement Grants
  11. GBT Announces Upcoming Data Presentations at 24th European Hematology Association (EHA) Congress Supporting Voxelotor Sickle Cell Disease Program
  12. Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
  13. Global Blood: 1Q Earnings Snapshot
  14. GBT Reports Recent Business Progress and First Quarter 2019 Financial Results
  15. When Will Global Blood Therapeutics, Inc. (NASDAQ:GBT) Breakeven?
  16. Did Hedge Funds Drop The Ball On Global Blood Therapeutics Inc (GBT) ?
  17. GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
  18. Announcing: Global Blood Therapeutics (NASDAQ:GBT) Stock Increased An Energizing 211% In The Last Three Years